Bremen, May 27, 2025 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading medical imaging software company, today announced its results for the first half of fiscal year 2024/2025, reporting period October 1, 2024 to March 31, 2025.
In the first half of the year, the Company's revenue amounted to € 8,438 thousand (previous year: € 8,774 thousand). Of this amount, 22% (previous year: 27%) was attributable to the sale of licenses, 34% (previous year: 35%) to maintenance revenues, and 44% (previous year: 38%) to other revenues, which include, among other things, services for and charges passed on to affiliated companies and the parent company. Earnings before interest and taxes (EBIT) fell from € 2,092 thousand to € 1,853 thousand, mainly due to lower sales compared with the previous year, higher other operating income and increased personnel expenses, corresponding to an EBIT margin of 22%.
Income from loans as financial assets amounted to € 550 thousand (previous year: € 258 thousand) and is attributable to interest income from the loan granted to Varex Imaging Deutschland AG. This results in earnings before taxes (EBT) of € 2,468 thousand (previous year: € 2,735 thousand).
Income taxes of € 64 thousand (previous year: € 74 thousand) were incurred in the first half of the year. Therefore, taking into account the expense from the profit to be transferred to Varex Imaging Deutschland AG in the amount of € 2,404 thousand (previous year: € 2,661 thousand), net income amounted to € 0 thousand (previous year: € 0 thousand). It should be noted that the expense from the transfer of earnings only arises legally at the end of the fiscal year.
At this point in time, we are sticking to our forecast: stable to slightly growing sales in the range of € 17.0 million to € 17.5 million are expected for the 2024/2025 financial year. In addition to stable sales with the customer Hologic, sales in the lung and liver segments are expected to increase slightly. We expect development services to remain stable. We expect earnings before interest and taxes (EBIT) for the financial year 2024/2025 to be between € 3.5 million and € 4.0 million, assuming a stable exchange rate of 1.12 USD/EUR. The forecast stability or slight increase in sales and the disproportionately low increase in personnel costs are the main drivers of the positive EBIT outlook.
The Executive Board will regularly review its expectations over the course of the 2024/2025 financial year on the basis of current business developments.